# Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

> **NCT05423717** · PHASE2 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 166 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** Daridorexant 10 mg
- **DRUG:** Daridorexant 25 mg
- **DRUG:** Daridorexant 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05423717
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-06
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-02-05
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05423717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05423717, "Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05423717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*